【摘要】：目的比較恩替卡韋聯(lián)合護肝布祖熱顆粒治療維吾爾族、漢族慢性乙型肝炎患者的臨床療效。方法采取前瞻性、配對研究方法,選取2015年1月至2015年5月新疆和田地區(qū)傳染病醫(yī)院就診的初始治療的慢性乙型肝炎患者為試驗組,維吾爾族:漢族按照4:1配對分組,維吾爾族300例,漢族75例,均接受恩替卡韋聯(lián)合護肝布祖熱顆粒治療12周,隨機抽取20例漢族慢性乙型肝炎患者與80例維吾爾族慢性乙型肝炎患者為對照組,僅使用恩替卡韋治療12周。觀察各組患者病毒學應(yīng)答率、血清學應(yīng)答率、生物化學應(yīng)答率以及不良反應(yīng)發(fā)生率。結(jié)果治療4周、8周、12周病毒完全應(yīng)答率分別為:試驗組中維吾爾族9.0%、20.7%、30.3%,漢族8.0%、21.3%、29.3%,對照組中維吾爾族2.5%、12.5%、21.3%,漢族5.0%、10.0%、20.0%;部分應(yīng)答率分別為:試驗組中維吾爾族48.3%、64.3%、69.3%,漢族46.7%、62.7%、64.0%,對照組中維吾爾族46.3%、62.5%、66.3%,漢族45.0%、65.0%、65.0%;生化學應(yīng)答率分別為:試驗組中維吾爾族88.7%、94.7%、99.3%,漢族85.3%、90.6%、98.6%,對照組中維吾爾族83.8%、87.5%、96.3%,漢族85.0%、90.0%、95.0%;血清學應(yīng)答率分別為:試驗組中維吾爾族31.7%、漢族29.3%、對照組中維吾爾族和漢族均為45.0%。治療前后各組患者均未見明顯臟器功能損傷。結(jié)論恩替卡韋聯(lián)合護肝布祖熱顆粒治療維吾爾族慢性乙型肝炎患者的療效比治療漢族慢性乙型肝炎患者的療效更好。
[Abstract]:Objective to compare the clinical efficacy of entecavir combined with Hugan Buzurie granule in the treatment of chronic hepatitis B in Uygur and Han nationality. Methods from January 2015 to May 2015, the patients with chronic hepatitis B (CHB) who were treated at the infectious disease hospital in Hetian region of Xinjiang were selected as the experimental group. The Uygur nationality: Han nationality were divided into two groups according to 4:1 pairing. 300 cases of Uygur nationality and 75 cases of Han nationality were treated with entecavir combined with Hugan Buzurie granule for 12 weeks. 20 patients with chronic hepatitis B of Han nationality and 80 patients with chronic hepatitis B of Uygur nationality were randomly selected as control group. Treatment with entecavir for 12 weeks only. The virological response rate, serological response rate, biochemical response rate and adverse reaction rate were observed. Results the complete response rates of the virus in the experimental group were as follows: in the test group, 9.0g and 20.7m, respectively, in the test group, in the control group, the Uygur group was 2.5-12.55.50.The partial response rates were as follows: in the test group, the Uygur nationality was 48.37.30% 64.34.33.The Han nationality was 46.7m and 62.7am 64.0, and the control group was 64.00.The partial response rates were as follows: in the test group, in the Uygur group, in the experiment group, in the control group. The biochemical response rates of the Uygur nationality in the experimental group were 88.7 / 94.74.70.The biochemical response rates were as follows: the biochemical response rates of the Uygur nationality in the experimental group were 88.7 / 94.74.799.30.The biochemical response rates of the Uygur nationality in the experimental group were 731.30, 29.3 respectively, and the control group was 83.87.56.36.30.The serological response rates of the Uygur nationality in the test group were 731.31. The Han nationality and the Han nationality in the control group were 731.30, 29.3and the control group, respectively. The biochemical response rates of the Uygur nationality in the experimental group were 731.30, 29.3 in the control group and 731.31 in the experimental group, respectively, in the control group, in the Uygur group, in the control group. Both er nationality and Han nationality were 45. 0%. Before and after treatment, there was no obvious injury of organ function in each group. Conclusion the curative effect of entecavir combined with Hugan Buzurei granule in treating Uygur patients with chronic hepatitis B is better than that of Han nationality patients with chronic hepatitis B.
【作者單位】： 首都醫(yī)科大學附屬北京佑安醫(yī)院急診科;新疆和田地區(qū)傳染病醫(yī)院肝病科;
【基金】：中國初級衛(wèi)生保健基金會資助項目(京佑基金【2015】第310號)
【分類號】：R512.62

【相似文獻】

相關(guān)期刊論文 前1條

1 吳濤;蔣嵐;阿吉艾克拜爾·艾薩;孫玉華;;護肝布祖熱顆粒提取新工藝及其對小鼠肝損傷保護作用的研究[J];中國中藥雜志;2011年04期

，

本文編號：2125279